Conference Roundup
Ocular Surface Disease

Advanced imaging tools can be incorporated into clinical trials for OSD for enhanced care

Posted on

Incorporating advanced imaging tools into interventional clinical trials for ocular surface diseases (OSDs) has “potential” to improve diagnostic capabilities. The findings were presented at the 2024 ARVO Annual Meeting in Seattle, Washington.

The study focused on the presentation and demonstration of the following advanced imaging modalities in randomized clinical trials for OSDs:

  • In vivo confocal microscopy
  • Anterior segment optical coherence tomography (AS-OCT)
  • Ocular surface analyzer (OSA)

Researchers showcased the capabilities of these tools when considering novel treatment options.

In vivo confocal microscopy was used to capture high-resolution images of the ocular surface layers, which the researchers said demonstrated its potential for cellular-level imaging and visualizing pathological changes associated with OSDs.

AS-OCT was used to provide detailed cross-sectional imaging of the anterior segment and to monitor the treatments’ effects, “emphasizing its role in assessing structural changes and potential applications in monitoring disease progression,” the researchers said.

OSA was used to simulate and analyze tear film dynamics, which may assist in understanding ocular surface health.

“These simulated presentations underscored the potential of these technologies in improving diagnostic capabilities and understanding OSDs, offering a glimpse into their potential application in future clinical settings for enhancing patient care and outcomes,” the authors concluded.


Recchioni A, Noeman M, Poonit N, Wallace GR, Rauz S. Advanced imaging tools for investigative medicinal products: towards new approaches for interventional randomized clinical trials in ocular surface disease. Abstract 3626-B0289. Presented at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting, May 5-9, Seattle, Washington.